Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens

Tirofiban is a glycoproteine (GP) IIb/IIIa receptor antagonist, which inhibits platelet-platelet aggregation and is a potential adjunctive antithrombotic treatment in patients with acute coronary syndromes (ACS) or high-risk percutaneous coronary interventions (PCI). It is administered intravenously...

Descripción completa

Detalles Bibliográficos
Autores principales: Heramvand, Nadia, Masyuk, Maryna, Muessig, Johanna M., Nia, Amir M., Karathanos, Athanasios, Polzin, Amin, Valgimigli, Marco, Gurbel, Paul A., Tantry, Udaya S., Kelm, Malte, Jung, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363357/
https://www.ncbi.nlm.nih.gov/pubmed/35482154
http://dx.doi.org/10.1007/s11239-022-02654-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363357/
https://www.ncbi.nlm.nih.gov/pubmed/35482154
http://dx.doi.org/10.1007/s11239-022-02654-0

Ejemplares similares